30
Mar

Novartis, a leader among companies using the immune system to fight cancer, is betting up to $750 million on a promising therapeutic approach from Aduro Biotech, widening its arsenal of potential treatments.

…read more

Source: Novartis tackles immuno-oncology with a $750M Aduro deal for new R&D group

    

0 No comments